Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481] by 
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
Cardiovascular Diabetology
Open Access Original investigation
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 
study: baseline characteristics and short-term effects of fenofibrate 
[ISRCTN64783481]
The FIELD Study Investigators*
Address: The FIELD Study, C/o NHMRC Clinical Trials Centre, Mallett St Campus, University of Sydney NSW 2006, Australia
Email: The FIELD Study Investigators* - FIELDTrial@ctc.usyd.edu.au
* Corresponding author    
Abstract
Objective:  The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study is
examining the effects of long-term fibrate therapy on coronary heart disease (CHD) event rates in
patients with diabetes mellitus. This article describes the trial's run-in phase and patients' baseline
characteristics.
Research design and methods: FIELD is a double-blind, placebo-controlled trial in 63 centres
in 3 countries evaluating the effects of fenofibrate versus placebo on CHD morbidity and mortality
in 9795 patients with type 2 diabetes mellitus. Patients were to have no indication for lipid-lowering
therapy on randomization, but could start these or other drugs at any time after randomization.
Follow-up in the study was to be for a median duration of not less than 5 years and until 500 major
coronary events (fatal coronary heart disease plus nonfatal myocardial infarction) had occurred.
Results: About 2100 patients (22%) had some manifestation of cardiovascular disease (CVD) at
baseline and thus high risk status. Less than 25% of patients without CVD had a (UKPDS
determined) calculated 5-year CHD risk of <5%, but nearly all had a 5-year stroke risk of <10%.
Despite this, half of the cohort were obese (BMI > 30), most were men, two-thirds were aged over
60 years, and substantial proportions had NCEP ATP III features of the metabolic syndrome
independent of their diabetes, including low HDL (60%), high blood pressure measurement or
treatment for hypertension (84%), high waist measurement (68%), and raised triglycerides (52%).
After a 6-week run-in period before randomisation with all participants receiving 200 mg
comicronized fenofibrate, there were declines in total and LDL cholesterol (10%) and triglycerides
(26%) and an increase in HDL cholesterol (6.5%).
Conclusion: The study will show the effect of PPAR-alpha agonist action on CHD and other
vascular outcomes in patients with type 2 diabetes including substantial numbers with low to
moderate CVD risk but with the various components of the metabolic syndrome. The main results
of the study will be reported in late 2005.
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Introduction
The cardiovascular benefits of long-term treatment using
HMG-CoA reductase inhibitors (statins) have been con-
clusively shown in several studies (summarized in [1]) of
people with and without established cardiovascular dis-
ease, which have included more than 18000 men and
women with diabetes mellitus [2-8]. To date, however, no
clinical trials using peroxisome proliferator-activated
receptor (PPAR) alpha agonists (such as fibrates) have
specifically examined cardiovascular event rate changes in
large numbers of patients with diabetes mellitus. In the 6
trials of fibrates reported to date the aggregate number of
patients with diabetes mellitus is just over 2000 [9-14],
with VA-HIT accounting for about 40% of these [11].
Fibrates cause favorable changes to the typical lipid profile
of type 2 diabetes mellitus, by raising high-density lipo-
protein (HDL) cholesterol, lowering triglycerides, and
reversing the tendency to formation of small, dense, low-
density lipoprotein (LDL) cholesterol particles [15-18].
If PPAR alpha agonists (and other modulators of the PPAR
axis) are to assume a role as mainstream agents for reduc-
ing the risk of fatal and nonfatal cardiovascular events,
adequately powered placebo-controlled trials, similar to
the statin trials, are needed. They should include patients
with diabetes of both sexes across a wide range of age and
absolute cardiovascular risk.
The Fenofibrate Intervention and Event Lowering in Dia-
betes (FIELD) Study is a 3-country (Australia, New Zea-
land and Finland), 63-centre, double-blinded placebo-
controlled trial evaluating the effects of fenofibrate com-
pared with placebo on coronary heart disease morbidity
and mortality in 9795 patients with type 2 diabetes [1].
The study incorporated a 6-week active-treatment run-in
period, with all subjects receiving 200 mg comicronized
fenofibrate before randomization to long-term placebo or
active treatment. This article reports the baseline and treat-
ment-entry characteristics of this cohort and defines the
absolute risk of its study population.
Methods
The design of the FIELD study has been described in detail
elsewhere [1]. The study was approved by local ethics
committees at each participating institution. In brief,
FIELD is a randomized double-blind, placebo-controlled,
parallel-group trial. Participants are middle-aged to eld-
erly people (50 to 75 years of age) with type 2 diabetes
mellitus considered to be at risk of coronary heart disease.
The first patient in FIELD was registered in November
1997 and randomized in February 1998. A total of 14 247
subjects were registered, and 13 900 were screened in clin-
ics for eligibility at Visit 1.
Patients were recruited from 63 centres in Australia, New
Zealand and Finland. Those with and without known vas-
cular disease were eligible for participation provided that,
at randomization, the usual physician considered that
there was no current indication for lipid-modifying treat-
ment. This meant that some patients meeting the FIELD
eligibility criteria for lipid levels were instead treated by
their usual doctors once they became aware of the
patients' lipid profile at screening; therefore, such patients
were not randomized and were not included in the study.
Patients with or without lipid abnormalities, such as low
HDL cholesterol or elevated triglycerides, were eligible if
the total blood cholesterol level at screening fell between
3.0 and 6.5 mmol/L (about 115–250 mg/dL) and either
the total-to-HDL cholesterol ratio was 4.0 or higher, or the
triglyceride level was over 1.0 mmol/L. Patients were
excluded if they had triglyceride levels over 5.0 mmol/L.
Lipid entry criteria were consistent with recruiting people
who would not qualify for fully subsidised lipid-modify-
ing treatment under the government guidelines in all 3
countries. Participants could not be taking any lipid-mod-
ifying therapy at the start of the dietary run-in period.
However, the protocol allows for statin or other lipid-low-
ering therapy to be added at any time after randomization
and recommends continuing study medication. The study
is thus evaluating the role of fenofibrate on a background
of usual care and will provide safety data on fibrate ther-
apy in combination with other lipid-lowering treatments.
A prespecified analysis will explore the effects of fenofi-
brate separately among those patients taking other lipid-
lowering agents during follow-up and those taking study
treatment alone. Intention-to-treat methods of analysis
will result in conservative estimates of any effects of fenof-
ibrate in the event that drop-ins to statin treatment are
more frequent in the placebo-treated group. Confounding
with respect to other drug use should be prevented by the
randomization process, which will result in good balance
across the treatment groups.
Patients known to have type 2 diabetes (identified
through hospital clinic records, diabetes society member-
ship lists and various patient registers) were invited to
attend a special clinic. After clinical screening of patients
for eligibility and obtaining informed consent, blood was
taken for biochemical measurements of fasting glucose,
lipids, apolipoproteins, fibrinogen, HbA1c, insulin, renal
and liver biochemistry, and homocysteine, and urine was
collected for albumin-to-creatinine ratio. The LDL choles-
terol level was calculated from the Friedewald formula
[19]. Biochemical analysis used standard methods in 2
central laboratories (Southpath, Flinders Medical Centre,
Adelaide, Australia, and the National Public Health Insti-
tute, Helsinki, Finland) which were aligned by using refer-
ence material from the Canadian External Quality
Assurance Laboratory, Vancouver, Canada, traceable backCardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
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to CDC, Atlanta, USA. Both laboratories participated in
local external quality assurance programs. Eligibility was
confirmed for consenting participants. All screened
patients were asked to follow agreed national dietary rec-
ommendations for type 2 diabetes mellitus and provided
with literature summarizing key dietary recommenda-
tions. Patients were asked to return after 4 weeks of dietary
adherence for review of their interest in participating in
the long-term trial, and for a check of laboratory eligibility
(triglyceride <5.0 mmol/L, serum creatinine <130 µmol/L,
alanine aminotransferase (ALT) less than twice the upper
limit of normal) and to commence a single-blind placebo
run-in phase of one capsule daily with breakfast for a fur-
ther 6-week period. Upon the patients' return after the
placebo period, consenting eligible patients were then
entered into a 6-week single-blind active run-in period.
During this time, they were to take comicronized fenofi-
brate 200 mg once daily. The placebo run-period was con-
ducted to familiarize patients with the long-term
commitment to the trial. The active run-in was conducted
to provide data on the short-term effects of fenofibrate
therapy on cholesterol levels for all randomized patients.
After the 16-week run-in procedures had been completed,
a further blood sample was taken at the time of randomi-
zation (week 0) to determine the short-term effects of the
comicronized fenofibrate on total cholesterol, HDL cho-
lesterol, triglycerides, LDL cholesterol and fibrinogen. At
this visit, patients were randomized, by a stratified adap-
tive randomization scheme, to receive either fenofibrate
(200 mg comicronized formulation) or matching long-
term placebo as one capsule daily with breakfast [1]. The
final patient was randomized to the study on 3 November
2000.
All patients were then followed up through regular visits
to a special clinic set in place for the purposes of the study
in addition to routine care provided through the family
doctor and usual diabetes clinics.
For a primary outcome of CHD events (CHD death plus
nonfatal MI), it is projected that approximately 500 CHD
events will have occurred when a median of 5 years of fol-
low-up has elapsed (during the first quarter of 2005); this
represents an event rate of approximately 1% per annum.
By this time the trial will have 80% power to detect an
observed 22% reduction in CHD events (based on the
intention-to-treat method of analysis). This will also pro-
vide 90% power to detect a 25% relative reduction in
CHD events (based on intention-to-treat analysis). These
calculations assumed an average drop-out rate from active
treatment of 10% over the course of the study but allowed
for a larger drop-in rate from placebo to open-cholesterol
treatment of 17%* by the mid-point of the trial and 32%
by study close, in view of the possible increased uptake of
statin therapy after the Heart Protection Study.7 (*This
was incorrectly referred to as 10% in the FIELD design
paper,1 the assumption used in the original power calcu-
lations.)
Therefore, follow-up in the study, as stipulated in the pro-
tocol, was to be for a median duration of not less than 5
years and until 500 major coronary events had occurred,
unless the study was terminated prematurely on the rec-
ommendation of the independent Safety and Data Moni-
toring Committee.
Results
Of the 13 900 patients screened in study clinics, 75.9%
(10 553) proceeded to enter the placebo run-in phase and
73.4% (10 203) the active run-in phase, and ultimately
9795 (70.5%) patients were randomized (Figure 1). The
demographic characteristics are shown for the rand-
omized and nonrandomized patients in Table 1. The
study cohort included more men than women, and had a
mean age in the mid-60s, and just over 2100 randomized
patients had a prior history of cardiovascular disease.
There were 6051 subjects randomized from Australia,
2351 from New Zealand and 1393 from Finland. There
were no differences across the 3 countries in mean ages of
patients or ages at diagnosis (55.8 years, 53.0 years and
56.2 years for Australia, Finland and New Zealand, respec-
tively). The median periods from diabetes diagnosis to
randomization were 5, 7 and 5 years, respectively. The
patients recruited were a mix from hospital and the com-
munity, and therefore were diverse in absolute risk. The
7664 participants who had no history of cardiovascular
disease were at lower risk on the basis of interim determi-
nation using the modified Framingham equation of the
UKPDS Risk Engine (Table 2) [20,21]. The prevalence
rates of the various components of the metabolic syn-
drome (using criteria from NCEP ATP III definitions) at
baseline are detailed in Table 3. A total of 84% of subjects
met the ATP III criteria for metabolic syndrome. Baseline
biochemistry for the entire randomized cohort and the
effects of the 6 weeks of treatment with comicronized
fenofibrate are shown in Table 4. On average, there was a
10% reduction in total cholesterol, a 10% reduction in
LDL cholesterol, a 26% reduction in triglycerides and a
6.5% increase in HDL cholesterol after this short-term
exposure to the active agent (average HDL increase was
6.1% in men versus 7.3% in women). Apolipoprotein B
levels fell by an average of 14%, and the total-to-HDL cho-
lesterol ratio by about 15%. Creatinine levels increased by
an average of nearly 13% (an effect that is believed to be
reversible and harmless, though not fully understood)
[22,23], and fibrinogen levels fell by 11%.Cardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
Page 4 of 9
(page number not for citation purposes)
Discussion
Almost all lipid-modifying trials that have included
patients with diabetes have used statins as the interven-
tion agent. Data on the effects of statin therapy among
more than 18000 persons with type 2 diabetes are now
available and show important reductions in coronary and
vascular events [24] . Those studies involving more than
1000 people with diabetes include Anglo-Scandinavian
Cardiac Outcomes Trial (ASCOT) [5], the Long-Term
Intervention with Pravastatin in Ischaemic Disease
(LIPID) study,[5] the Antihypertensive and Lipid-Lower-
ing Treatment to Prevent Heart Attack Trial (ALLHAT-LLT)
[4], the Heart Protection Study [7] and the most recently
reported trial, the Collaborative Atorvastatin Diabetes
Study (CARDS). CARDS used atorvastatin, 10 mg/day,
and showed a 36% reduction in combined cardiovascular
endpoints (2.46% per year for placebo and 1.54% for
atorvastatin-treated) [8]. The results from a similarly
structured trial (Atorvastatin Study for Prevention of Cor-
onary Heart Disease Endpoints in Non Insulin Dependent
Diabetes Mellitus, ASPEN) are pending.
Two large-scale trials of fibrate therapy have also been
completed: the Veterans Low-HDL Cholesterol Interven-
tion Trial (VA-HIT) and the Bezafibrate Infarct Prevention
(BIP) trial enrolled subjects with and without diabetes
mellitus. Both studies were limited to people with prior
myocardial infarction and reported reductions in major
cardiovascular events among participants with low HDL
and high triglycerides at baseline, which were greater than
with use of the same fibrate among those without dyslip-
idemia [11,25]. The VA-HIT trial also reported lower cor-
onary heart disease mortality in those with diabetes
receiving gemfibrozil and reduced cardiovascular events,
though rates of nonfatal myocardial infarction did not
change significantly [11]. A third, smaller, trial that used a
fibrate, the Diabetes Atherosclerosis Intervention Study
(DAIS), showed reduced progression of established coro-
nary atherosclerosis among those randomized to fenofi-
brate compared with those receiving matching placebo
over 3 years [10].
The identification of the PPAR transcription factor as the
primary pathway through which fibrate and glitazone-
agonist actions are triggered [18] has stimulated renewed
interest in the antiatherogenic effects of these agents.
PPAR-alpha activation by fibrates has the potential to pre-
vent atherosclerosis via regulation of lipid metabolism
and hemostatic pathways [26,27]. Consequently, there is
great interest in the FIELD study because it will generate
clinical information about fibrates in diabetes similar to
that which is already available for the statins.
These baseline data of the FIELD study cohort without
known prior cardiovascular disease show that over half
Numbers of patients enrolled in the run-in phases of the trial Figure 1
Numbers of patients enrolled in the run-in phases of the trial.
Registered
14 247 
Attended clinic for screening 
13 900 (100%) 
Entered dietary run-in period 
13 562 (97.6%) 
Randomised 
9795 (70.5%) 
Entered placebo run-in period 
10 553 (75.9%) 
Entered active run-in period 
10 203 (73.4%) Cardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
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Table 1: Baseline characteristics of the FIELD study cohort
Characteristic Category Screened, not 
randomized
(n = 4105)
Randomized
(n = 9795)
n % n %
Sex Male 2424 59.0 6138 62.7
Female 1681 41.0 3657 37.3
Age at Visit 1 (years) <55 682 16.6 1668 17.0
55–59 802 19.5 1976 20.2
60–64 856 20.8 2196 22.4
65–69 888 21.7 2202 22.5
70+ 877 21.4 1753 17.9
Ethnicity* Caucasian 3757 91.5 9093 92.8
Indigenous 161 3.9 258 2.6
Asian 93 2.3 141 1.4
Other 94 2.3 303 3.1
Body mass index (kg/m2) (BMI) BMI < 25 805 19.6 1198 12.2
25 ≤ BMI < 30 1511 36.8 3855 39.4
30 ≤ BMI < 35 1099 26.8 2869 29.3
BMI ≥ 35 652 15.9 1866 19.1
Waist (cm) Female (mean ± SD) 98 ± 15 101 ± 14
Male (mean ± SD) 103 ± 13 105 ± 12
Waist-hip ratio ratio < 0.8 242 5.9 333 3.4
0.8 ≤ ratio < 0.9 1184 28.8 2531 25.8
0.9 ≤ ratio < 1.0 1931 47.0 4942 50.5
1.0 ≤ ratio < 1.1 645 15.7 1797 18.4
ratio ≥ 1.1 73 1.8 179 1.8
Smoking (cigarettes) Nonsmoker 1735 42.3 4000 40.8
Ex-smoker 1933 47.1 4908 50.1
Current smoker 404 9.8 887 9.1
Clinical history Prior cardiovascular disease † 1045 25.4 2131 21.8
Prior myocardial infarction 278 6.7 485 5.0
Stroke 194 4.7 346 3.5
Angina 588 14.3 1188 12.1
Hypertension 2247 54.7 5544 56.6
Claudication or peripheral vascular disease 351 8.6 711 7.2
Transient ischemic attack 155 3.8 307 3.1
Prior coronary revascularisation No CABG or PTCA 3908 95.2 9432 96.3
CABG only 122 3.0 230 2.4
PTCA only 49 1.2 102 1.0
CABG and PTCA 26 0.6 31 0.3
Diabetes management Diet only 1119 27.3 2542 26.0
Diet + OH only 2238 54.5 5874 60.0
Diet + insulin 429 10.5 569 5.8
Diet + OH + insulin 319 7.8 810 8.3
Diabetic complications ‡ Retinopathy 431 10.5 814 8.3
Neuropathy 636 15.5 1394 14.2
Nephropathy 161 3.9 279 2.9
Skin ulcers 139 3.4 299 3.1
Amputations 106 2.6 176 1.8
Diabetes diagnosis ‡ Age at diagnosis (mean ± SD) 54.8 ± 8.7 55.5 ± 8.3
Median duration of diabetes in years (quartile 1, quartile 3) 6 (2, 11) 5 2, 10
* Patients are assumed to be Caucasian unless otherwise stated. Indigenous includes Aborigines, Torres Strait Islanders, Maori and Pacific Islanders. 
Other includes mixed races, African-American, Indian, African, etc.
† Prior cardiovascular disease is defined as a reported history of myocardial infarction, angina (stable and unstable), coronary revascularization 
(CABG or PTCA), stroke, claudication or peripheral vascular disease or peripheral revascularization before randomization. The count includes 13 
randomized patients and 10 nonrandomized patients who suffered or reported a cardiovascular event during the run-in period (visit 1 to visit 4 
(randomization)).
‡ Diabetic complications and age at diabetes diagnosis are self-reported.
CABG = coronary artery bypass grafting; PTCA = percutaneous transluminal coronary angioplasty; SD = standard deviation; OH = oral 
hypoglycemic agentsCardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
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Table 2: Distribution of projected 5-year risk (%, UKPDS risk engine) of coronary and other vascular outcomes for randomized 
patients with no history of cardiovascular disease (n = 7664)
Outcome 
measures
Projected 5-year risk (%, from the UKPDS risk engine)
<5% 5%–<10% 10%–<15% 15%–<20% ≥20%
All CHD 24.6 37.0 20.7 9.5 8.2
Fatal CHD 56.1 26.8 9.9 4.6 2.6
All stroke 79.3 17.0 2.8 0.7 0.2
Fatal stroke 99.9 0.1 0.0 0.0 0.0
Table 3: Prevalence of various components of the metabolic syndrome among the 9795 randomized participants in the FIELD study
Men
 (n = 6138)
Women
 (n = 3657)
Total
 (n = 9795)
Metabolic syndrome feature: ATPIII criteria * n % n % n %
Waist measurement (women >88 cm; men >102 cm) 3613 58.9 3034 83.0 6647 67.9
Triglycerides >= 1.7 mmol/L 3073 50.1 2020 55.2 5093 52.0
HDL (men <40 mg/dL; women <50 mg/dL) 3365 54.8 2455 67.1 5820 59.4
Hypertension (SBP >= 130 and DBP >= 85 mm Hg) 5050 82.3 3131 85.6 8181 83.5
Fasting glucose >= 110 mg/dL or diabetes 6133 99.9 3646 99.7 9779 99.8
* When 3 of the 5 listed characteristics are present, a diagnosis of metabolic syndrome is established (84% of the cohort met the criteria)
Table 4: Baseline fasting biochemistry for the 9795 randomized participants in the FIELD study
Baseline After 6 weeks of 
fenofibrate||
Parameter Mean SD Median Q1, Q3 Mean SD
Total cholesterol (mmol/L) 5.04* 0.69 5.03* 4.56, 5.54 4.49 0.69
HDL cholesterol (mmol/L)¶ 1.10* 0.26 1.06* 0.92, 1.24 1.16 0.29
Calculated LDL cholesterol (mmol/L) 3.07* 0.64 3.08* 2.62, 3.51 2.71 0.62
Triglycerides (mmol/L) 1.94* 0.88 1.74* 1.34, 2.34 1.37 0.63
Total-to-HDL cholesterol ratio 4.81* 1.10 4.71* 4.04, 5.49 4.08 1.13
Apolipoprotein B (g/L) 0.97* 0.17 0.97* 0.86, 1.09 0.83 0.18
Creatinine (mmol/L) 0.08† 0.02 0.08† 0.07, 0.09 0.09 0.02
Fibrinogen (g/L) 3.6† 0.8 3.6† 3.1, 4.1 3.12 0.75
Fasting glucose (mmol/L) 8.9† 2.6 8.5† 7.0, 10.3 -- --
Urinary albumin-to-creatinine ratio (mg/mmol) 5.9† 21.8 1.2† 0.7, 3.0 -- --
Homocysteine (µmol/L) 10.2§ 3.7 9.5§ 7.9, 11.6 -- --
Insulin (mU/L) 15.7‡ 24.0 12.0‡ 8.0, 18.5 -- --
HbA1c (%) 7.1† 1.4 6.9† 6.1, 7.8 -- --
* Average of Visit 2 and Visit 3.
† Average of Visit 1 and Visit 3.
‡ Visit 1 only.
§ Visit 3 only.
¶ Baseline HDLc (mean ± SD): men = 1.03 ± 0.23 mmol/L, women = 1.21 ± 0.28 mmol/L
|| All changes at six weeks were statistically significant at P < 0.0001 
-- not measuredCardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
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such patients had a (UKPDS-determined) calculated 5-
year coronary heart disease risk of less than 10% and
nearly all patients had a stroke risk of less than 10% over
5 years. Part of the reason for this low-risk status may be
that the duration of diabetes was only 5 years, on average,
and reflecting this short duration, the median HbA1c was
6.9% for the entire cohort and the proportion of patients
using no diabetes glucoregulatory therapy was just over a
quarter. This probably reflects the recruitment process, in
that many community-based subjects chose to enter the
study in response to information provided by newsletters
sent through Diabetes Australia, the Finnish Diabetes
Society, the New Zealand Society for the Study of Diabetes
and a New Zealand national diabetes consumer database.
Nonetheless, the cohort still had a profile with many char-
acteristics of high cardiovascular risk. Half of the patients
were obese (BMI > 30), most were male, two-thirds were
over the age of 60 years, and substantial proportions had
NCEP ATP III features of the metabolic syndrome addi-
tional to their diabetes mellitus, including low HDL cho-
lesterol, either high blood pressure measurement and/or
treatment for hypertension, high waist measurement and
raised triglyceride. Over 2100 (22%) had established car-
diovascular disease, and 39% of those without known car-
diovascular disease had a projected 5-year absolute risk of
a coronary event higher than 10%.
Evaluation of the effect of comicronized fenofibrate over
6 weeks immediately before randomization was included
in the protocol. The purpose of this was to measure the
effect of the agent in the entire cohort. After 6 weeks there
were major reductions in triglycerides, lesser decreases in
LDL cholesterol, and rises in HDL cholesterol. Creatinine
levels rose while fibrinogen fell, several of the effects that
have been observed elsewhere and with other fibrate
agents [28,29].
Approximately 140 million adults were estimated to have
diabetes mellitus in 1997; it is the most common
endocrine disorder worldwide. Projections put diabetes
prevalence by 2010 at 221 million, about 60 percent
higher. Just as many people again have an elevated fasting
glucose level, or impaired fasting glucose, which can
progress rapidly to diabetes [30]. Without the FIELD study
data, doctors would remain uncertain about the merits of
using PPAR-alpha agonists, with or without concomitant
statin therapy, when confronted with a patient with diabe-
tes mellitus. The study will have special application to
showing the effect of PPAR alpha agonist action on cardi-
ovascular outcomes in those with low HDL dyslipidemic
profiles. The main results of the FIELD study will be
reported in late 2005.
Declaration of competing interests
Of the Management Committee of the FIELD Study:
PB, YAK and RS have received reimbursements, fees, fund-
ing, or salary in the past five years from an organization
that may in any way gain or lose financially from the pub-
lication of this paper;
No authors hold or have held stocks or shares in such an
organization;
No authors have other financial competing interests;
AK has the following nonfinancial competing interest:
Advisory board membership.
Authors' contributions
The Writing Committee are the authors responsible for
this article.
Study organization
Writing committee
R Scott, J Best, P Forder, M-R Taskinen, J Simes, P Barter, A
Keech
Management Committee
P Barter*, J Best*, P Colman, M d'Emden, T Davis, P
Drury, C Ehnholm, P Glasziou, D Hunt, A Keech* (study
chairman and principal investigator), YA Kesaniemi, M
Laakso, R Scott*, RJ Simes*, D Sullivan, M-R Taskinen*, M
Whiting; J-C Ansquer, B Fraitag (non-voting sponsor rep-
resentatives). * Executive Committee members
Outcomes Assessment Committee
N Anderson, G Hankey, D Hunt (chairman), S Lehto, S
Mann, M Romo; LP Li (outcomes officer, in attendance),
Safety and Data Monitoring Committee
C Hennekens, S MacMahon (chairman), S Pocock, A
Tonkin, L Wilhelmsen; P Forder (unblinded statistician,
in attendance).
Site Principal investigators
Australia: H Akauola, F Alford, P Barter, I Beinart, J Best, S
Bohra, S Boyages, P Colman, H Connor, D Darnell, T
Davis, P Davoren, F Lepre, F De Looze, M d'Emden, A
Duffield, R Fassett, J Flack, G Fulcher, S Grant, S Ham-
wood, D Harmelin, R Jackson, W Jeffries, M Kamp, L
Kritharides, L Mahar, V McCann, D McIntyre, R Moses, H
Newnham, G Nicholson, R O'Brien, K Park, N Petrovsky,
P Phillips, G Pinn, D Simmons, K Stanton, B Stuckey, D R
Sullivan, M Suranyi, M Suthers, Y Tan, M Templer, D Top-
liss, J H Waites, G Watts, T Welborn, R Wyndham; Fin-
land: H Haapamaki, A Kesaniemi, M Laakso, J Lahtela, H
Levanen, J Saltevo, H Sodervik, M Taskinen, M Vanhala;Cardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
Page 8 of 9
(page number not for citation purposes)
New Zealand: J Baker, A Burton, P Dixon, J Doran, P
Drury, P Dunn, N Graham, A Hamer, J Hedley, J Lloyd, P
Manning, I McPherson, S Morris, C Renner, R Scott, R
Smith, M Wackrow, S Young.
Co-investigators and site coordinators
Australia: F Alard, J Alcoe, F Alford, C Allan, J Amerena, R
Anderson, N Arnold, T Arsov, D Ashby, C Atkinson, L
Badhni, M Balme, D Barton, B Batrouney, C Beare, T Beat-
tie, J Beggs, C Bendall, C Bendall, A Benz, A Bond, R Brad-
field, J Bradshaw, S Brearley, D Bruce, J Burgess, J Butler,
M Callary, J Campbell, K Chambers, J Chow, S Chow, K
Ciszek, P Clifton, P Clifton-Bligh, V Clowes, P Coates, C
Cocks, S Cole, D Colquhoun, M Correcha, B Costa, S Cov-
erdale, M Croft, J Crowe, S Dal Sasso, W Davis, J Dunn, S
Edwards, R Elder, S El-Kaissi, L Emery, M England, O
Farouque, M Fernandez, B Fitzpatrick, N Francis, P Free-
man, A Fuller, D Gale, V Gaylard, C Gillzan, C Glatthaar,
J Goddard, V Grange, T Greenaway, J Griffin, A Grogan, S
Guha, J Gustafson, P S Hamblin, T Hannay, C Hardie, A
Harper, G Hartl, A Harvey, S Havlin, K Haworth, P Hay, L
Hay, B Heenan, R Hesketh, A Heyworth, M Hines, G
Hockings, A Hodge, L Hoffman, L Hoskin, M Howells, D
Hunt, A Hunt, W Inder, W Inder, D Jackson, A
Jovanovska, K Kearins, P Kee, J Keen, D Kilpatrick, J Kin-
dellan, M Kingston-Ray, M Kotowicz, A Lassig, M Layton,
S Lean, E Lim, F Long, L Lucas, D Ludeman, D Ludeman,
C Ludeman-Robertson, M Lyall, L Lynch, C Maddison, B
Malkus, A Marangou, F Margrie, K Matthiesson, J Mat-
thiesson, S Maxwell, K McCarthy, A McElduff, H McKee, J
McKenzie, K McLachan, P McNair, M Meischke, A Merkel,
C Miller, B Morrison, A Morton, W Mossman, A Mowat, J
Muecke, P Murie, S Murray, P Nadorp, S Nair, J Nairn, A
Nankervis, K Narayan, N Nattrass, J Ngui, S Nicholls, V
Nicholls, JA Nye, E Nye, D O'Neal, M O'Neill, S O'Rourke,
J Pearse, C Pearson, J Phillips, L Pittis, D Playford, L Porter,
L Porter, R Portley, M Powell, C Preston, S Pringle, W A
Quinn, J Raffaele, G Ramnath, J Ramsden, D Richtsteiger,
S Roffe, S Rosen, G Ross, Z Ross, J Rowe, D Rumble, S
Ryan, J Sansom, C Seymour, E Shanahan, S Shelly, J Shep-
herd, G Sherman, R Siddall, D Silva, S Simmons, R Simp-
son, A Sinha, R Slobodniuk, M Smith, P Smith, S Smith, V
Smith-Orr, J Snow, L Socha, T Stack, K Steed, K Steele, J
Stephensen, P Stevens, G Stewart, R Stewart, C Strakosch,
M Sullivan, S Sunder, J Sunderland, E Tapp, J Taylor, D
Thorn, D Thorn, A Tolley, D Torpy, G Truran, F Turner, J
Turner, J van de Velde, S Varley, J Wallace, J Walsh, J
Walsh, J Walshe, G Ward, B Watson, J Watson, A Webb, F
Werner, E White, A Whitehouse, N Whitehouse, S Wigg, J
Wilkinson, E Wilmshurst, D Wilson, G Wittert, B Wong, M
Wong, S Worboys, S Wright, S Wu, J Yarker, M Yeo, K
Young, J Youssef, R Yuen, H Zeimer, R W Ziffer; Finland:
A Aura, A Friman, J Hanninen, J Henell, N Hyvarinen, M
Ikonen, A Itkonen, J Jappinen, A Jarva, T Jerkkola, V Jok-
inen, J Juutilainen, H Kahkonen, T Kangas, M Karttunen,
P Kauranen, S Kortelainen, H Koukkunen, L Kumpu-
lainen, T Laitinen, M Laitinen, S Lehto, R Lehto, E Lei-
nonen, M Lindstron-Karjalainen, A Lumiaho, J Makela, K
Makinen, L Mannermaa, T Mard, J Miettinen, V Naatti, S
Paavola, N Parssinen, J Ripatti, S Ruotsalainen, A Salo, M
Siiskonen, A Soppela, J Starck, I Suonranta, L Ukkola, K
Valli, J Virolainen; New Zealand: P Allan, W Arnold, W
Bagg, K Balfour, T Ball, B Ballantine, C Ballantyne, C
Barker, C Barker, F Bartley, E Berry, G Braatvedt, A Camp-
bell, T Clarke, R Clarke, A Claydon, S Clayton, P Cress-
well, R Cutfield, J Daffurn, J Delahunt, A Dissnayake, C
Eagleton, C Ferguson, C Florkowski, D Fry, P Giles, M Glu-
yas, C Grant, P Guile, M Guolo, P Hale, M Hammond, M
Hammond, P Healy, M Hills, J Hinge, J Holland, B Hyne,
A Ireland, A Johnstone, S Jones, G Kerr, K Kerr, M Khant,
J Krebs, L Law, B Lydon, K MacAuley, R McEwan, P McGre-
gor, B McLaren, L McLeod, J Medforth, R Miskimmin, J
Moffat, M Pickup, C Prentice, M Rahman, E Reda, C Ross,
A Ryalls, D Schmid, N Shergill, A Snaddon, H Snell, L Ste-
vens, A Waterman, V Watts.
Coordinating centre teams
NHMRC Clinical Trials Centre, Sydney: K Jayne, E Keir-
nan, P Newman, G Ritchie, A Rosenfeld (project direc-
tors), E Beller, P Forder, V Gebski, A Pillai (study
statisticians), C Anderson, S Blakesmith, S-Y Chan, S
Czyniewski, A Dobbie, S Doshi, A Dupuy, S Eckermann,
M Edwards, N Fields, K Flood, S Ford, C French, S Gillies,
C Greig, M Groshens, J Gu, Y Guo, W Hague, S Healy, L
Hones, Z Hossain, M Howlett, J Lee, L-P Li, T Matthews, J
Micallef, A Martin, I Minns, A Nguyen, F Papuni, A Patel,
J Pearse, R Pike, M Pena, K Pinto, D Schipp, J Schroeder, B
Sim, C Sodhi, T Sourjina, C Sutton, R Taylor, P Vlagsma, S
Walder, R Walker, W Wong, J Zhang, B Zhong, A Keech
(deputy director), RJ Simes (director); Helsinki Project
Office: A Kokkonen, P Narva, E-L Niemi, A Salo, A-M Syr-
janen, M-R Taskinen (director); Christchurch Project
Office: C Lintott, R Scott (director).
Central laboratories
Adelaide: R Tirimacco, M Whiting; Helsinki: C Ehnholm,
M Ikonen, M Kajosaari, L Raman, J Sundvall, M Tukianen.
Laboratoires Fournier SA liaison: Dijon: J-C Ansquer, B
Fraitag, D Crimet, I Sirugue, Sydney: P Aubonnet.
Acknowledgements
The FIELD study is supported by a grant from Laboratoires Fournier SA, 
Dijon, France and is being coordinated independently by the National 
Health and Medical Research Council Clinical Trials Centre, University of 
Sydney, Sydney, Australia, and overseen by the study Management 
Committee.
The study is also supported by the National Health and Medical Research 
Council, Australia (Unit grant, Project grant, and Fellowships to A. Keech 
and J. Simes), without which it would not be possible. We thank the Cardiovascular Diabetology 2005, 4:13 http://www.cardiab.com/content/4/1/13
Page 9 of 9
(page number not for citation purposes)
National Heart Foundation, Australia, Diabetes Australia, Diabetes New 
Zealand, and the Finnish Diabetes Association for endorsing the study. 
Investigators express their thanks to Rhana Pike for her assistance with the 
preparation of this manuscript. Finally, the many patients participating in the 
FIELD study are thanked for their untiring contributions.
References
1. FIELD Study Investigators: The need for a large-scale trial of
fibrate therapy in diabetes: the rationale and design of the
Fenofibrate Intervention and Event Lowering in Diabetes
(FIELD) study. ISRCTN64783481.  Cardiovasc Diabetol 2004, 3:9.
2. Scandinavian Simvastatin Survival Study Group: Randomised trial of
cholesterol lowering in 4444 patients with coronary heart
disease; the Scandinavian Simvastatin Survival Study (4S).
Lancet 1994, 344:1383-1389.
3. Goldberg RB, Mellies MJ, Sacks FM, Moye LA, Howard BV, Howard
WJ, Davis BR, Cole TG, Pfeffer MA, Braunwald E: Cardiovascular
events and their reduction with pravastatin in diabetic and
glucose-intolerant myocardial infarction survivors with aver-
age cholesterol levels: subgroup analyses in the cholesterol
and recurrent events (CARE) trial. The Care Investigators.
Circulation 1998, 98:2513-2519.
4. ALLHAT Officers and Coordinators for the ALLHAT Collaborative
Research Group: The Antihypertensive and Lipid-Lowering
Treatment to Prevent Heart Attack Trial: Major outcomes
in moderately hypercholesterolemic, hypertensive patients
randomized to pravastatin vs usual care: The Antihyperten-
sive and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT-LLT).  JAMA 2002, 288:2998-3007.
5. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M,
Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Niem-
inen M, O'Brien E, Ostergren J, ASCOT investigators, et al.: Preven-
tion of coronary and stroke events with atorvastatin in
hypertensive patients who have average or lower-than-aver-
age cholesterol concentrations, in the Anglo-Scandinavian
Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-
LLA): a multicentre randomised controlled trial.  Lancet 2003,
361:1149-1158.
6. Keech AC, Colquhoun D, Best J, Kirby A, Simes RJ, Hunt D, Hague
W, Beller E, Arulchelvam M, Baker J, Tonkin A, for the LIPID study
group, et al.: Secondary prevention of cardiovascular events
with long-term pravastatin in patients with diabetes or
impaired fasting glucose: results from the LIPID trial.  Diabe-
tes Care 2003, 26:2713-2721.
7. Heart Protection Study Collaborative Group: MRC/BHF Heart
Protection Study of cholesterol lowering with simvastatin in
5963 people with diabetes: a randomised placebo-controlled
trial.  Lancet 2003, 361:2005-2016.
8. Colhoun HM, Betteridge DJ, Durington PN, Hitman GA, Neil HA, Liv-
ingstone SJ, Thomason MJ, Mackness MI, Charlton-Menys V, Fuller JH,
on behalf of the CARDS Investigators: Primary prevention of car-
diovascular disease with atorvastatin in type 2 diabetes in
the Collaborative Atorvastatin Diabetes Study (CARDS);
multicentre randomised placebo controlled trial.  Lancet 2004,
364:685-696.
9. The BIP Study Group: Secondary prevention by raising HDL
cholesterol and reducing triglycerides in patients with coro-
nary artery disease. The Bezafibrate Infarction Prevention
(BIP) Study.  Circulation 2000, 102:21-27.
10. Diabetes Atherosclerosis Intervention Study Investigators: Effect of
fenofibrate on progression of coronary artery disease in type
2 diabetes: the Diabetes Atherosclerosis Intervention Study,
a randomised study.  Lancet 2001, 357:905-910.
11. Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ,
Faas FH, Anderson JW, for the VA-HIT Study Group: Diabetes,
plasma insulin and cardiovascular disease. Subgroup analysis
from the Department of Veterans Affairs high-density lipo-
protein intervention trial (VA-HIT).  Arch Intern Med 2002,
162:2597-2604.
12. Elkeles RS, Diamond JR, Poulter C, Dhanjil S, Nicolaides A, Mahmood
S, Richmond W, Mather H, Sharp P, Feher MD: Cardiovascular
outcomes in type 2 diabetes: A double-blind placebo-con-
trolled study of bezafibrate: The St. Mary's, Ealing, North-
wick Park Diabetes Cardiovascular Disease Prevention
(SENDCAP) Study.  Diabetes Care 1998, 21:641-642.
13. Meade T, Zuhrie R, Cook C, Cooper J, on behalf of MRC: General
Practice Research Framework: Bezafibrate in men with
lower extremity arterial disease: randomized controlled
trial.  BMJ 2002, 325:1-5.
14. Koskinen P, Mänttäri M, Manninen V, Huttunen JK, Heinonen OP,
Frick MH: Coronary heart disease incidence in NIDDM
patients in the Helsinki Heart Study.  Diabetes Care 1992,
15:820-825.
15. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyorala K, Penttila I:
Serum lipids and lipoproteins in middle aged non-insulin
dependent diabetics.  Atherosclerosis 1985, 56:271-281.
16. Feingold KR, Grunfeld C, Pang M, Doerrler W, Krauss RM: LDL sub-
class phenotypes and triglyceride metabolism in non-insulin
dependent diabetes.  Arterioscler Thromb 1992, 12:1496-1502.
17. Staels B, Dallongeville J, Auwerx J, Schoonjans K, Leitersdorf E, Fru-
chart JC: Mechanisms of action of fibrates on lipid and lipopro-
tein metabolism.  Circulation 1998, 98:2088-2093.
18. Schoonjans K, Staels B, Auwerx J: Role of the peroxisome prolif-
erator-activated receptor (PPAR) in mediating the effects of
fibrates and fatty acids on gene expression.  J Lipid Res 1996,
37:907-925.
19. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the con-
centration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge.  Clin Chem
1972, 18:499-502.
20. Stevens RJ, Kothari V, Adler AI, Stratton IM, Holman RR: The
UKPDS risk engine: a model for the risk of coronary heart
disease in type II diabetes (UKPDS 56).  Clin Sci 2001,
101:671-679.
21. Kothari V, Stevens RJ, Adler AI, Stratton IM, Manley SE, Neil HA, Hol-
man RR: UKPDS 60: risk of stroke in type 2 diabetes esti-
mated by the UK Prospective Diabetes Study risk engine.
Stroke 2002, 33:1776-1781.
22. Westphal S, Dierkes J, Luley C: Effects of fenofibrate and gemfi-
brozil on plasma homocysteine.  Lancet 2001, 358:39-40.
23. Ansquer J-C, Foucher C, Rattier S, Taskinen M-R, Steiner G, for the
DAIS Investigators: Fenofibrate reduces progression to micro-
albuminuria over three years in a placebo-controlled study
in type 2 diabetes : results from the Diabetes Atherosclerosis
Intervention Study (DAIS).  Am J Kidney Dis 2005, 44:485-493.
24. Cholesterol Treatment Trialists’ Collaborators: Efficacy and safety
of cholesterol-lowering treatment: prospective meta-analy-
sis of data from 90 056 participants in 14 randomised trials of
statins.  Lancet 2005, 366:1267-1278.
25. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S:
Bezafibrate for the secondary prevention of myocardial inf-
arction in patients with metabolic syndrome.  Arch Int Med
2005, 165:1154-1260.
26. Rizos E, Mikhailidis DP: Are high-density lipoprotein and triglyc-
eride levels important in secondary prevention: impressions
from the BIP and VA-HIT trials.  Int J Cardiol 2002, 82:199-207.
27. Keating GM, Ormrod D: Micronised fenofibrate. An updated
review of its clinical efficacy in the management of
dyslipidaemia.  Drugs 2002, 62:1909-1944.
28. Elisaf M: Effects of fibrates on serum metabolic parameters.
Curr Med Res Opin 2002, 18:269-276.
29. Genest J, Frohlich J, Steiner G: Effect of fenofibrate-mediated
increase in plasma homocysteine on the progression on cor-
onary artery disease in type 2 diabetes mellitus.  Am J Cardiol
2004, 93:848-853.
30. Cameron AJ, Shaw JE, Zimmet PZ: The metabolic syndrome:
prevalence in worldwide populations.  Endocrinol Metab Clin
North Am 2004, 33:351-375.